Locations:
They generally depend on the mutated gene, clone size and clinical setting
Large analysis adds to evidence that absolute diameter alone may miss vulnerable patients
Procedure places the center among only a handful worldwide to offer the minimally invasive approach
Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran
Durability findings propel potential one-time treatment approach to phase 1b testing
Practical takeaways for the reality of overlapping cardiovascular, kidney and metabolic disease
First prospective study shows early extubation and low vasoactive/inotropic medication use
Height-indexed aortic measurements may better identify risk than diameter alone
Insights from an expert cardiologist and a transplant surgeon
Advertisement
Advertisement
Search